BVS: Safe Also in Peripheral Territory

Original Title: Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I) 2-Year Clinical and Imaging Results CME.

Reference: Johannes Lammer et al. J Am Coll Cardiol Intv. 2016;9(11):1178-1187.

 

BVS Peripheral TerritoryThis is the first study on humans to assess the bioresorbable everolimus eluting vascular scaffold for the treatment of peripheral artery disease involving the external iliac and superficial femoral arteries.

After the success of new bioresorbable scaffolds in coronary territory, it was only a matter of time before they tested this new technology in peripheral territory.

The ESPRIT BVS is an everolimus-eluting poly-l-lactide scaffold and it was tested for the first time in 35 patients with intermittent claudication.

88.6% of treated lesions were in the superficial femoral artery and 11.4% in the external iliac artery. Lesion mean length was 35.7 ± 16.0 mm and devices were successfully deployed in all patients, without recoil.

Three patients presented minor complications such as puncture site hematoma or post implantation dissection.

At one year, binary restenosis resulted in 12.1%. At two years, 16.1%. Not all patients required revascularization:

At one year: 8.8%.

At two years: 11.8%.

The ankle brachial index improved from 0.75 ± 0.14 at baseline to 0.96 ± 0.16 at two years.

At 2 years, 71% of patients were in Rutherford class 0, and 93.5% of the population had achieved maximum walking distance of 500 m.

 

Conclusion

Safety of the bioresorbable everolimus eluting scaffold was shown, with a low rate of revascularization consistent with duplex-ultrasonography showing sustained patency at two years.

 

Editorial Comment

Treated lesions, as in most of first-in-man studies that test new devices, were short and with no total occlusions. Severely calcified lesions are frequent in femoropopliteal territory and are a real challenge for this new devices.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or any ideas here below.

 

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...